2019 China biopharmaceutical innovation and cooperation conference has come to a successful end. I look forward to seeing you next year!

"2019 China biomedical innovation and cooperation conference" was held in Shanghai on September 26-27 This conference was hosted by Wanyi medicine, CO organized by Shanghai Biomedical Industry Association, Shanghai Pudong New Area Biological Industry Association, business office of the U.S Embassy and consulate in China, Zhangjiang life and health industry (incubation) alliance, Shanghai junrun Network Technology Co., Ltd., Baihua Association, Hong Kong Biological Industry Association Supported by science and Technology Association, tongshuyi, new drug founder's club, Shanghai equity investment Association, Yaodu, xialan investment, Haimen science and Technology Park, touhu.com, Guangdong Medical Valley, Wuhan East Lake National Independent Innovation Demonstration Zone biomedical industry association, etc The plenary session of the general assembly was presided over by Dr Hua Ye of Yihui pharmaceutical Mr Dong Shupei from the biomedical Department of Shanghai Science and Technology Committee was invited to make a detailed interpretation on the planning and policies of Shanghai biomedical industry Dr Feng Hui of Shanghai Junshi biology Co., Ltd shared the topic of "opportunities, challenges and solutions of Chinese innovative drugs" Dr Ji Qunsheng of Wuxi apptec made a wonderful report on "platform of immunotranslational medicine to help research and development of new tumor immune drugs" Later, Mr Yu Cong, chairman of Shanghai Changxing Marine Equipment Park, took the stage to discuss Changxing and win in the future as the topic of investment promotion for Shanghai Changxing marine equipment Industrial Park, and introduced the future planning and policies of the park in detail The interactive round table discussion "deepening the drug review and approval system and accelerating the R & D and marketing of new drugs in China" was hosted by Dr huayie of Yihui pharmaceutical, who had an in-depth discussion for one hour together with Dr Zhang Haizhou, Dr Yang Jianxin and Dr LV Yuzhen of Roche (China) In the interactive round table discussion on "exploring the development and innovative cooperation mode of tumor immunotherapy antibody", Dr Yiming Ketian Wenzhi as the chair of Jiabin, Dr Yang Jianxin and elixiron of cornerstone pharmaceutical industry Dr Chen Hongkai and Dr Liao maijing of platinum medicine were guests for the discussion Dr Zhang Yi of Hualing pharmaceutical introduced the mechanism and clinical research progress of glucose homeostasis regulation of dorzagliatin, a new generation of diabetes drug Mr Norbert prenzel from sotio shared the topic of building an oncology specialty pharma company Mr Yang Xiaodong of KPMG shared the information management of drug R & D cost tracing Dr Luo Jin of Jiangsu Antai biology made a keynote speech on "dendritic cell therapy technology based on sea-map load" The interactive round table discussion -- car-t product development, application and clinical treatment application progress, presided over by Dr Lu Lulu of Heyuan biology, ended successfully in the intense brainstorming of Dr Zhang Liang of bangyao biology, Dr Sun Wenjun of Yao junuo, Dr Zhang Jishuai of prekin biology and Dr Hui Li of Sorrento therapeutics Inc The interactive round table discussion, presided over by Mr Ye Yin of Ping An Securities, attended by Mr Gao Lei of Harbin Pharmaceutical Group, Ms Wu Yixia of junshengtai, Mr Zhou Yujian of power capital and Dr Xu Meng of thoughtway, focuses on the investment and financing opportunities of China's pharmaceutical industry Dr Dong min, the chair of sub forum 2 and the first round table discussion in the afternoon, asked Dr Wei Ziping, Dr Dan Bo, and Dr Chen Zhaorong of BLS, Dr Deqi pharmaceutical, and Dr Xikang bio under the topic of research and development difficulties and market prospects of macromolecular bio innovative drugs According to the research status and risk control of tumor immunotherapy drugs, Dr Ma Jing of Shanghai new drug safety evaluation and Research Center issued his own views Huang Tao's general principles of Shenzhen intelligent pharmaceutical technology share the application of machine learning technology in new drug research and development General manager Shen Yuelei introduced a new model of antibody drug research and development: a one-stop research and development platform based on all human antibody renmab mice and in vivo efficacy Jin Bo general principles of Sanyou biology delivered a keynote speech on the integrated high-throughput R & D service platform for innovative antibody drugs Dr Peng bin shared the development and future layout of bispecific antibody Dr Rowan of Suoyuan biology delivered a keynote speech on precision medicine, which started in China and faced the world: Suoyuan biology's unique and innovative new drug model Dr Wu Youling of teras Pharmaceutical Co., Ltd also shared his views on the past, present and future of ADC product development Dr Bian Feng of Pfizer introduced how to research and develop new drugs based on innovation and cooperation Dr Zhou Zhou, tuozhen biology, has brought about the current situation and strategy of Nash research Dr He Qi shared the application and Prospect of high-throughput single cell analysis platform in innovative drug research and development In response to the current hot discussion on oncolytic virus, the conference invited two experts in this field - Dr Zhou Guoying of Yinuo micro medicine and Dr Liu binlei of Binhui biology, who made wonderful reports respectively Mr Nie Yan and Mr Gao Huanyong from Shengzhi law firm made a keynote speech on the international perspective of patent application in the field of biopharmaceutical With Dr Li Fang of platinum medicine, he shared "the platform of all human antibody transgenic mice to help develop innovative tumor immunotherapy" Ms Christy Ma of lion TCR brought the keynote speech of opportunity and barrier in cell therapy clinical research Mr Liu Ming, CST, made a keynote speech on the multidisciplinary cooperation of ptmscan ® technology to promote the discovery and commercialization of tumor biomarkers Wang Di, general manager of Beijing panshengzi gene, shared the topic of "precise biomarker detection based on ngs platform to assist drug research and development" Mr Yang Xin, director of investment promotion of Shanghai Lingang Changxing Technology City, as a representative of Lingang Changxing Technology City, shared the theme report of "Lingang Changxing - creating value for industry" Dr Yao Du and Dr Li Jing took the lead in the round table discussion - "emerging new methods and technologies of drug research and development" and invited Dr parexel Fengsheng, Dr Guo Xiang, Dr Baiji Shenzhou, Dr Xue Fubo, Dr Junshi biology and Dr medidate Chen Zhiyang Taiwan & US biomedical special session the conference is divided into two major biomedical special sessions in Taiwan and the United States As the host of the special session, Dr Zhang Haoteng of Rongyu capital invited Dr Chen Hongkai of elixiron immunologies Inc., Mr Shen Weihong, Mr Jing Kai, Dr stone Yingzhu, Dr Jian Duxian and Dr Wang Zhaohui, the original doctor Huang Chengchao, deputy director of Anting Town People's Government of Jiading District, Shanghai, made an industrial recommendation for Anting Town on the theme of seizing the opportunity of development and building a highland of precision medical industry Mr Xueke, management committee of Taizhou pharmaceutical high tech park, introduced the functions and functions of the specialized Park in the innovation and development of biomedicine In the US special session, we invited Mr Mao Hua from Frost & Sullivan consulting, Mr Wang Ningling from Feihan law firm, Dr Hui Li from Sorrento therapeutics Inc., Dr Wu Min from Mosha, Dr Wang Yajun from Illumina, Ms Yang Yuehong from Berkeley lights, Inc., Ms Angela Feng from xynomic pharmaceuticals to deliver wonderful reports Thanks to the support of Shanghai Changxing Marine Equipment Park, Changxing science and technology park near the port and Shanghai Olympic spectrum Enterprise Service Center, the conference held a special dinner on the evening of the 26th Nearly 150 famous people, including relevant government officials, industry and association leaders, well-known enterprise representatives, gathered together to build a feast for the global biomedical industry Thank you again for your support! With the help of various industry experts and enterprises, this conference is a perfect conclusion! Thank you for the support of 70 + speakers, 10 + cooperation organizations, 30 + cooperative enterprises and 40 + cooperative media! The organizing committee will continue to work closely with outstanding experts and enterprises in the industry to build the most influential platform for biomedical industry in China We are looking forward to meeting you at the 2nd China biomedical innovation and cooperation conference in 2020!